• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    4/8/24 12:31:21 PM ET
    $AGEN
    $ANL
    $CNSP
    $ETAO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGEN alert in real time by email

    Gainers

    • Etao International Co (NASDAQ:ETAO) stock moved upwards by 96.6% to $4.9 during Monday's regular session. The company's market cap stands at $25.0 million.
    • Longeveron (NASDAQ:LGVN) shares moved upwards by 48.63% to $3.27. The market value of their outstanding shares is at $8.2 million.
    • Adlai Nortye (NASDAQ:ANL) stock rose 47.3% to $12.21. The market value of their outstanding shares is at $450.3 million.
    • Onconetix (NASDAQ:ONCO) stock moved upwards by 26.56% to $0.21. The company's market cap stands at $4.6 million.
    • MSP Recovery (NASDAQ:LIFW) stock rose 24.42% to $1.63. The market value of their outstanding shares is at $24.1 million.
    • Outset Medical (NASDAQ:OM) shares moved upwards by 21.95% to $2.5. The market value of their outstanding shares is at $126.2 million.

    Losers

    • Universe Pharmaceuticals (NASDAQ:UPC) shares fell 18.2% to $1.75 during Monday's regular session. The market value of their outstanding shares is at $6.3 million.
    • Agenus (NASDAQ:AGEN) shares fell 17.55% to $0.42. The company's market cap stands at $173.9 million.
    • MiNK Therapeutics (NASDAQ:INKT) shares fell 13.47% to $1.35. The market value of their outstanding shares is at $46.8 million.
    • CNS Pharma (NASDAQ:CNSP) stock decreased by 13.42% to $0.22. The company's market cap stands at $1.8 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares declined by 12.37% to $1.67. The market value of their outstanding shares is at $4.0 million.
    • Vincerx Pharma (NASDAQ:VINC) stock decreased by 12.35% to $4.87. The market value of their outstanding shares is at $104.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGEN
    $ANL
    $CNSP
    $ETAO

    CompanyDatePrice TargetRatingAnalyst
    Adlai Nortye Ltd.
    $ANL
    2/13/2026$16.00Neutral → Buy
    H.C. Wainwright
    MiNK Therapeutics Inc.
    $INKT
    8/15/2025$35.00Neutral → Buy
    H.C. Wainwright
    MiNK Therapeutics Inc.
    $INKT
    7/14/2025Outperform → Mkt Perform
    William Blair
    Agenus Inc.
    $AGEN
    6/4/2025$25.00Neutral → Buy
    H.C. Wainwright
    Adlai Nortye Ltd.
    $ANL
    6/2/2025Buy → Neutral
    H.C. Wainwright
    Longeveron Inc.
    $LGVN
    12/6/2024$10.00Buy
    ROTH MKM
    Adlai Nortye Ltd.
    $ANL
    9/4/2024$9.00Buy
    H.C. Wainwright
    Outset Medical Inc.
    $OM
    8/8/2024$6.00 → $3.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $AGEN
    $ANL
    $CNSP
    $ETAO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Longeveron Announces Private Placement of up to $30 Million

    $15 million upfront with a milestone-driven potential additional $15 million related to the Company's anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsInitial proceeds extend cash runway into 4Q26, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions,

    3/10/26 9:00:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

    Work orders for key CMC and production activities activate first contingent payment as global demand expands across clinical and paid compassionate access programs Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The payment was triggered by contracted work orders for critical chemistry, manufacturing and controls (CMC) and production activities related to botensilimab (BOT) and balstilimab (BAL). These activities will allow Zydus to perform the initiation of its commercial supply of Agenus' lead programs. Th

    3/10/26 7:30:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

    Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before the market opens on Monday, March 16, 2026. Agenus will host a stakeholder briefing webcast in late March to spotlight key strategic plans, data milestones and provide an update on the global botensilimab (BOT) and balstilimab (BAL) development program. About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination

    3/4/26 4:30:00 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    $ANL
    $CNSP
    $ETAO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Armen Garo H was granted 4,994 shares, increasing direct ownership by 2% to 330,535 units (SEC Form 4)

    4 - AGENUS INC (0001098972) (Issuer)

    3/9/26 4:15:05 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Technology Officer Faulkner Eric

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    3/4/26 5:02:29 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Faulkner Eric

    3 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    3/4/26 5:02:02 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGEN
    $ANL
    $CNSP
    $ETAO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baluch Khoso bought 11,766 shares, increasing direct ownership by 29% to 52,516 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:07 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Locklear Lisa bought 11,766 shares, increasing direct ownership by 5% to 250,964 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Ruiz John Hasan bought $12,115 worth of shares (50,000 units at $0.24), increasing direct ownership by 3% to 1,791,406 units (SEC Form 4)

    4 - MSP Recovery, Inc. (0001802450) (Issuer)

    8/28/24 4:05:11 PM ET
    $LIFW
    EDP Services
    Technology

    $AGEN
    $ANL
    $CNSP
    $ETAO
    SEC Filings

    View All

    CNS Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    3/11/26 8:35:29 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form F-3 filed by Adlai Nortye Ltd.

    F-3 - Adlai Nortye Ltd. (0001944552) (Filer)

    3/10/26 8:47:00 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Longeveron Inc.

    PRE 14A - Longeveron Inc. (0001721484) (Filer)

    3/3/26 7:59:59 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGEN
    $ANL
    $CNSP
    $ETAO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Adlai Nortye Ltd. upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Adlai Nortye Ltd. from Neutral to Buy and set a new price target of $16.00

    2/13/26 9:51:23 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MiNK Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded MiNK Therapeutics from Neutral to Buy and set a new price target of $35.00

    8/15/25 8:13:07 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MiNK Therapeutics downgraded by William Blair

    William Blair downgraded MiNK Therapeutics from Outperform to Mkt Perform

    7/14/25 8:40:54 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    $ANL
    $CNSP
    $ETAO
    Leadership Updates

    Live Leadership Updates

    View All

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Outset Medical Reports Unaudited Fourth Quarter and 2025 Results

    SAN JOSE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, and named Karen N. Prange to its board of directors. Unaudited Fourth Quarter and 2025 Results Revenue in the fourth quarter totaled approximately $28.9 million, bringing revenue for 2025 to approximately $119.5 million, a 5% increase over $113.7 million in 2024.Exiting 2025, more than 1,000 sites of care have insourced dialysis with Outset, performing roughly 1 million treatments per year and more t

    1/12/26 8:30:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

    Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel (AAC) program. BOT is an Fc-enhanced multifunctional CTLA-4 antibody and BAL is a PD-1 antibody. In combination, BOT/BAL is being investigated in patients with microsatellite-stable colorectal cancer (MSS CRC), a population that has hi

    11/18/25 8:41:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    $ANL
    $CNSP
    $ETAO
    Financials

    Live finance-specific insights

    View All

    Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026

    SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2025 after the close of trading on Wednesday, February 11, 2026. On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 p.m. Pacific time (4:30 p.m. E

    1/26/26 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation

    New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive funding from NIH- and philanthropic grantsLaunching Phase 2+ trial in severe pulmonary disease in US population with FDA-validated endpointsAdded national leaders in pulmonary medicine, trauma, and biodefense join MiNK management (Dr. Hammond) and Board (Dr. Holcomb) to drive pivotal developmentCash runway extended through 2026, enabling multiple inflection points NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneeri

    11/14/25 7:30:00 AM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

    France grants reimbursed access with patients having commenced treatment Two-year BOT/BAL survival presented at ESMO spanning more than five cancers in over 400 patients Phase 3 on track to commence in fourth quarter 2025 Agenus Inc. (NASDAQ:AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate access (AAC) in France for botensilimab plus balstilimab (BOT/BAL), new survival data presented at ESMO and ESMO‑GI across more than 400 patients spanning more than five refractory cancers, and initiation of the global Phase 3 BATTMAN trial. Access & Regulatory Franc

    11/10/25 7:30:00 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGEN
    $ANL
    $CNSP
    $ETAO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Agenus Inc.

    SC 13G/A - AGENUS INC (0001098972) (Subject)

    11/14/24 7:58:18 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

    SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

    11/14/24 4:41:42 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care